drugset / Trial / NCT02859519

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

NCT02859519

Phase 3 Completed 365 enrolled Moberg Pharma AB
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.

Timeline

Start
2016-10
Primary completion
2019-11-13
Completion
2019-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Terbinafine Small molecule 10 % Topical

Indications